Key facts
- This page summarizes Randolph C. Read's Form 4 filing for ENZON PHARMACEUTICALS, INC. (ENZN).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 16 Jun 2023, 16:05.
Randolph C. Read - 14 Jun 2023 Form 4 Insider Report for ENZON PHARMACEUTICALS, INC. (ENZN)
- Reporting relationship
- Director
- Issuer ticker
- ENZN
- Reported as of
- 14 Jun 2023
- Net transaction value
- +$13,909
- SEC form
- 4
- Accepted by SEC
- 16 Jun 2023, 16:05:38 UTC
- Prior SEC filing
- 15 Aug 2022
- Next SEC filing
- 14 Jun 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Randolph C. Read
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Randolph C. Read filed Form 4 for ENZON PHARMACEUTICALS, INC. (ENZN) on 16 Jun 2023.
Change
- Previous filing in this sequence was filed on 15 Aug 2022.
- Current net transaction value: +$13,909.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ENZN
transaction
Common Stock
Purchase
- Transaction value
- $1,988
- Shares
- +15,000
- Change %
- +15%
- Price
- $0.1325
- Shares after
- 115,450
- Date
- 14 Jun 2023
- Ownership
- Direct
ENZN
transaction
Common Stock
Purchase
- Transaction value
- $11,922
- Shares
- +84,550
- Change %
- +73%
- Price
- $0.1410
- Shares after
- 200,000
- Date
- 16 Jun 2023
- Ownership
- Direct
* marks a reported price that did not pass the local price check.